MedTrace Logo

Calcitriol, Physical Activity, and Bone Health in Cancer Survivors

NCT00904033 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2019-04-23

Study results available
· View outcomes & findings →

Summary

Both the calcitriol and exercise interventions are aimed at reducing fracture risk by maintaining proper bone density, thereby preventing osteoporotic/osteopenic conditions and increasing muscle mass. Both calcitriol and exercise are efficacious in maintaining proper bone health and muscle mass among the general population, but little research has been done on breast cancer patients and survivors. The combination of calcitriol and exercise, which function through different but similar mechanisms, could produce interactive effects in reducing fracture risk among breast cancer survivors.

Hypothesis: A combination of calcitriol along with a structured home-based walking and progressive resistance exercise program will be efficacious in preventing bone resorption and in increasing bone formation among survivors of invasive breast cancer.

Conditions

  • Breast Neoplasms
  • Bone and Bones

Interventions

DRUG

Calcitriol

Calcitriol tablet taken once per week.

BEHAVIORAL

Exercise

Exercise consisting of progressive walking and resistance band training

DIETARY_SUPPLEMENT

Multivitamin

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Luke J Peppone, Ph.D. · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-01
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904033 on ClinicalTrials.gov